3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
2
Ureteral Neoplasms
2
Carcinoma, Transitional Cell
2
Urothelial Cancer
1
Urologic Neoplasms
1
Urethral Neoplasms
1
Triple Negative Breast Neoplasms
1
Metastatic Urothelial Cancer
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Gemcitabine
7
Cisplatin
5
Ramucirumab
3
Platinum
3
Paclitaxel
3
Docetaxel
3
1,2-diaminocyclohexaneplatinum II citrate
3
pembrolizumab
2
Carboplatin
2
rucaparib
1
pegfilgrastim
1
pazopanib
1
eribulin
1
enzalutamide
1
enfortumab vedotin
1
dehydroftorafur
1
cabozantinib
1
avelumab
1
atezolizumab
1
aflibercept
1
Taxes
1
Surgical Procedures, Operative
1
Sunitinib
1
Standard of Care
1
Specimen Handling
1
Sorafenib
1
Radiotherapy
1
Radiation
1
N-(3-aminopropyl)-N-(1-(5-benzyl-3-methyl-4-oxo-(1,2)thiazolo(5,4-d)pyrimidin-6-yl)-2-methylpropyl)-4-methylbenzamide
1
Mitozytrex
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Urethral Neoplasms
×
enfortumab vedotin
×
Clear all
NCT03219333
2024-08-27
EV-201
Astellas Pharma Inc
Phase 2
Completed
219 enrolled
32 charts
2 FDA